BUSINESS● LOWSep 3 · Sep 3, 2026, 12:57 PM
Alumis downgraded at Guggenheim after trial setback for SLE candidate
Seeking Alpha Tech · north america
Alumis, a company, was downgraded by Guggenheim following a trial setback for its candidate drug for Systemic Lupus Erythematosus (SLE).
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS48m agoGlass Lewis backs activist's bid to replace entire Ethan Allen boardSeeking Alpha TechBUSINESS1h agoWeil’s incoming leader to walk away from top job as law firm faces talent crisisFinancial Times